For every week the shutdown lasts, the agency’s research-only hospital will turn away approximately 200 patients – 30 of them children – who often seek participation in experimental studies after more traditional methods have failed, National Institutes of Health (NIH) Director Dr. Francis Collins told AP.
Though prospective NIH patients are usually eligible for studies at other hospitals around the country, “this is the place where people have wanted to come when all else has failed,” Collins said. “It’s heartbreaking.”
A child with a life-threatening illness is likely the only exception, Collins said, and existing patients will continue to receive care at the NIH Clinical Center in Bethesda.
In addition, he said that all experimental studies are on hold as long as Congress cannot settle on a budget deal.
“If you expected new treatments for cancer or a new universal influenza vaccine or discovering the causes of autism were going to move forward at the maximum it could, that will not be the case,” Collins said. “This is a profoundly discouraging day.”
For the 2013 fiscal year that ended Monday, the NIH was only able to fund around 16 percent of the research grant applications it received. A decade ago, one in three of such applications were funded by the NIH, which lost $1.5 billion of its $31 billion budget due to sequester spending cuts earlier this year.
The NIH is scheduled to lose $600 million more from a second round of cuts, meaning that further projects that will not be funded, Collins said.
Beyond the NIH, a continuing government shutdown will also impact operations at the Centers for Disease Control (CDC) in Atlanta, Georgia.
According to a memo put out by the Department of Health and Human Services, the CDC will be “unable to support the annual seasonal influenza program, outbreak detection and linking across state boundaries using genetic and molecular analysis, continuous updating of disease treatment and prevention recommendations” as well as curtail “support to state and local partners for infectious disease surveillance.”